Can canagliflozin give a boost to insulin resistance and inner fats tissue in sufferers with kind 2 diabetes higher than metformin?

Posted through on Might 31, 2022 in Diabetes mellitus |

In a nutshell

This learn about assessed the consequences of canagliflozin (Invokana) remedy on frame composition, glucose keep an eye on, insulin resistance, and systemic (complete frame) irritation in sufferers with newly-diagnosed kind 2 diabetes (T2D) in comparison to metformin (Glucophage). The knowledge confirmed that canagliflozin remedy decreased visceral fats tissue, and advanced blood glucose, insulin resistance, and systemic irritation in those sufferers.

Some background

A primary reason behind T2D is insulin resistance. Because of this the frame can’t correctly use insulin to decrease blood glucose. The primary drug repeatedly given to newly identified sufferers with T2D is metformin, which improves insulin resistance. 

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) akin to canagliflozin are oral glucose-lowering medication used within the remedy of diabetes. SGLT2is would possibly considerably scale back the chance of center illness and protracted kidney failure in sufferers with diabetes. Insulin resistance and protracted irritation had been connected to an higher waist circumference (stomach weight problems) in sufferers with T2D.

It’s unknown whether or not enhancements in insulin resistance and blood glucose ranges with SGLTi remedies are associated with lowered stomach fats tissue. Dapagliflozin (Farxiga), a kind of SGLT2i, has proven promising ends up in waist/hip ratio discounts, a marker for stomach weight problems, after 12 weeks of remedy. On the other hand, it’s unclear whether or not that is because of decreased visceral fats tissue in sufferers with T2D and if those results additionally prolong to canagliflozin.

Strategies & findings

This learn about incorporated 140 sufferers with newly-diagnosed T2D. Sufferers had been assigned to two remedy teams. Crew 1 incorporated 67 sufferers who won 100 mg of canagliflozin as soon as day-after-day for 12 weeks. Crew 2 incorporated 73 sufferers who won 1000 mg of metformin, twice-daily for 12 weeks. Fats tissue pictures had been acquired the use of stomach cross-sections with computed tomography. Laboratory measurements and fasting insulin ranges (mIU/mL) the use of the Homeostatic Fashion Evaluation of Insulin Resistance (HOMA-IR) had been decided.

After 12 weeks of remedy with canagliflozin, fasting blood glucose, HbA1c (blood glucose keep an eye on during the last 2-3 months), and HOMA-IR had been lowered, at the side of visceral (inner stomach) fats tissue, in comparison to baseline measurements. Canagliflozin remedy ended in decrease fasting blood glucose, HbA1c, HOMA-IR, visceral fats tissue, and inflammatory blood markers in comparison to metformin remedy.

The base line

The learn about confirmed that canagliflozin remedy ended in better enhancements in blood glucose keep an eye on and insulin resistance and visceral fats aid in comparison to metformin in sufferers with newly identified T2D.

The superb print

The learn about was once achieved in a unmarried middle and was once non-randomized. Researchers and sufferers had been conscious about the assigned remedy teams, doubtlessly permitting bias to be offered. 

Printed Through :

BMC endocrine issues

Date :

Feb 10, 2022

Authentic Identify :

Results of canagliflozin and metformin on insulin resistance and visceral adipose tissue in other folks with newly-diagnosed kind 2 diabetes.

For customized updates relating to diabetes mellitus:

For customized updates relating to diabetes mellitus:

Oops. Used to be this no longer related for you?

When you join Medivizor, you can obtain PERSONALIZED updates which might be JUST FOR YOU. Wish to give it a take a look at?

Share Us

Inquiry Now